Nanosonics Ltd
ASX:NAN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.96
5.02
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
NAN
stock under the Base Case scenario is
2.84
AUD.
Compared to the current market price of 4.17 AUD,
Nanosonics Ltd
is
Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Nanosonics Ltd.
| JP |
|
Hoya Corp
TSE:7741
|
|
| CH |
|
Alcon AG
SIX:ALC
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Nanosonics’ heavy dependence on its flagship Trophon system creates a concentration risk. Any disruption—whether through competing infection-control solutions or disruptive new technology—could significantly undermine sales and profitability, given the lack of diversified revenue streams.
Relatively slow adoption in key international markets could stall the firm’s growth trajectory. Different national regulations and purchasing practices may lengthen sales cycles, and an inability to forge effective local partnerships could hinder further market penetration.
Significant R&D expenditures, coupled with expansion efforts, risk diluting margins if new products fail to achieve expected sales. Overinvestment in unproven systems could drain cash resources and limit near-term returns.
Trophon’s leading position in high-level ultrasound probe disinfection, supported by growing regulatory scrutiny of infection control measures, provides Nanosonics with a robust and recurring revenue stream from both new system placements and consumable sales.
Adoption of automated and consistent disinfection processes is on the rise worldwide, creating a favorable tailwind for Nanosonics. The company’s established relationships with major ultrasound manufacturers and hospitals position it well to capitalize on this trend.
Nanosonics’ solid balance sheet with low debt levels gives it flexibility to invest in new infection-control technologies and expand into adjacent markets, potentially diversifying revenue and strengthening its competitive moat.
Revenue & Expenses Breakdown
Nanosonics Ltd
Balance Sheet Decomposition
Nanosonics Ltd
| Current Assets | 225.3m |
| Cash & Short-Term Investments | 161.6m |
| Receivables | 38.8m |
| Other Current Assets | 24.9m |
| Non-Current Assets | 47.2m |
| PP&E | 24.4m |
| Intangibles | 1k |
| Other Non-Current Assets | 22.8m |
| Current Liabilities | 39.8m |
| Accounts Payable | 10.6m |
| Accrued Liabilities | 10.1m |
| Other Current Liabilities | 19.1m |
| Non-Current Liabilities | 22.8m |
| Long-Term Debt | 4.3m |
| Other Non-Current Liabilities | 18.5m |
Free Cash Flow Analysis
Nanosonics Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Nanosonics Ltd
|
Revenue
|
198.6m
AUD
|
|
Cost of Revenue
|
-43.3m
AUD
|
|
Gross Profit
|
155.4m
AUD
|
|
Operating Expenses
|
-137.4m
AUD
|
|
Operating Income
|
18m
AUD
|
|
Other Expenses
|
2.7m
AUD
|
|
Net Income
|
20.7m
AUD
|
NAN Profitability Score
Profitability Due Diligence
Nanosonics Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Nanosonics Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
NAN Solvency Score
Solvency Due Diligence
Nanosonics Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Nanosonics Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NAN Price Targets Summary
Nanosonics Ltd
According to Wall Street analysts, the average 1-year price target for
NAN
is 4.7 AUD
with a low forecast of 3.79 AUD and a high forecast of 5.7 AUD.
Dividends
Current shareholder yield for
NAN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NAN
stock under the Base Case scenario is
2.84
AUD.
Compared to the current market price of 4.17 AUD,
Nanosonics Ltd
is
Overvalued by 32%.